• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Fetter Trevor was granted 712 shares, increasing direct ownership by 7% to 10,705 units (SEC Form 4)

    10/7/25 4:41:34 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care
    Get the next $OMDA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    FETTER TREVOR

    (Last) (First) (Middle)
    C/O OMADA HEALTH, INC.
    611 GATE WAY BLVD., SUITE 120

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Omada Health, Inc. [ OMDA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    10/05/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 10/05/2025 A 712(1) A $0 10,705 D
    Common Stock 111,200 I See footnote(2)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program.
    2. Shares held by a limited liability company of which the Reporting Person is the sole member.
    Remarks:
    /s/ Nathan Salha, as Attorney-in-Fact for Trevor Fetter 10/07/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OMDA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OMDA

    DatePrice TargetRatingAnalyst
    9/5/2025$24.00Neutral
    Robert W. Baird
    7/1/2025$21.00Outperform
    Evercore ISI
    7/1/2025$25.00Overweight
    Morgan Stanley
    7/1/2025$19.00Overweight
    Analyst
    7/1/2025$23.00Buy
    Needham
    7/1/2025$21.00Overweight
    Barclays
    7/1/2025$29.00Buy
    Goldman
    7/1/2025$27.00Buy
    Canaccord Genuity
    More analyst ratings

    $OMDA
    SEC Filings

    View All

    SEC Form 10-Q filed by Omada Health Inc.

    10-Q - Omada Health, Inc. (0001611115) (Filer)

    11/7/25 4:04:47 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Omada Health, Inc. (0001611115) (Filer)

    11/6/25 4:07:06 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Omada Health Inc.

    SCHEDULE 13G/A - Omada Health, Inc. (0001611115) (Subject)

    11/5/25 11:40:14 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $OMDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Robert W. Baird initiated coverage on Omada Health with a new price target

    Robert W. Baird initiated coverage of Omada Health with a rating of Neutral and set a new price target of $24.00

    9/5/25 8:00:48 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Evercore ISI initiated coverage on Omada Health with a new price target

    Evercore ISI initiated coverage of Omada Health with a rating of Outperform and set a new price target of $21.00

    7/1/25 8:41:36 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Morgan Stanley initiated coverage on Omada Health with a new price target

    Morgan Stanley initiated coverage of Omada Health with a rating of Overweight and set a new price target of $25.00

    7/1/25 8:21:32 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Root Jonathan D was granted 657 shares, increasing direct ownership by 7% to 10,630 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    10/7/25 4:42:40 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Fetter Trevor was granted 712 shares, increasing direct ownership by 7% to 10,705 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    10/7/25 4:41:34 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Director Hilleman Jeryl L was granted 1,126 shares, increasing direct ownership by 11% to 11,238 units (SEC Form 4)

    4 - Omada Health, Inc. (0001611115) (Issuer)

    10/7/25 4:41:26 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Leadership Updates

    Live Leadership Updates

    View All

    Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users

    SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada's behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not. Previous clinical studies have suggested that sustained weight loss leads to increased long-term health benefits,¹ including the reduction of comorbidities, and persistence on a GLP-1 is associate

    11/4/25 12:00:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health Welcomes Thomas Tsang, MD, MPH as Chief Medical Officer

    SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced the appointment of Thomas Tsang, MD, MPH as Chief Medical Officer. Dr. Tsang brings extensive experience in academia, clinical care delivery, and health information technology. In this role, he will lead Omada's clinical organization while advancing clinical quality, outcomes, strategy, and innovation across Omada's multi-condition platform. "Dr. Tsang's exceptional track record in building a virtual care delivery platform makes him the ideal clinical leader to help drive Omada's next phase of growth," said Sean Duffy, CEO and Co-Founder of Omada Heal

    10/27/25 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health Launches "Meal Map," an AI-Powered Nutrition Experience Focused on Nutrient Quality, Not Calorie Counting

    The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new real-time, personalized nutrition guidance SAN FRANCISCO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, launches Meal Map, a new nutrient-categorization tool that combines AI-powered instant feedback with human care teams to help members in its cardiometabolic programs understand the nutrient quality of their food choices. Built within Omada's Nutritional Intelligence capability, Meal Map is designed to help members make informed food choices, with an aim towards fostering confidence a

    10/1/25 9:00:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Omada Health Announces GLP-1 Prescribing Capability to Support Growing Member Population

    SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual-first, between-visit health care provider, today announced the planned launch of its prescribing capability. After reporting 53% year-over-year member growth as of the end of Q3, the company is also expanding its offerings. A new option of prescribing and medication management of anti-obesity medications (AOM), including GLP-1s, will be available in Omada's evidence-based behavior change weight health program, to tailor support before, during, and after medication treatment. "Omada is preparing for the next era of obesity care - one with broader access to GLP-1 medications of various types and price p

    11/6/25 4:10:20 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health Reports Third Quarter 2025 Results

    Revenue of $68 million, up 49%; 53% Member GrowthSignificant Reduction in Net Loss and First Quarter of Positive Adjusted EBITDAAnnounces New GLP-1 Prescribing Offering SAN FRANCISCO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Omada Health, Inc. (NASDAQ:OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2025. 2025 Third Quarter Highlights Total members of 831,000, up 53% compared with the third quarter of 2024Revenue of $68 million, up 49% compared with the third quarter of 2024Prescribing offering: announced plans to launch a new prescribing offering that will combine Omada's evidence-based behavior change program

    11/6/25 4:10:12 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health to Present Real-World Evidence at ObesityWeek 2025 Demonstrating Enhanced Outcomes for Current and Former GLP-1 Users

    SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, announced it will present two posters at ObesityWeek 2025 highlighting the potential impact of Omada's behavior change program on members currently or previously on GLP-1 medications for weight loss. Together, these analyses suggest that engagement with Omada may enhance results for members who have been on GLP-1s for weight loss, whether they stay on the medication or not. Previous clinical studies have suggested that sustained weight loss leads to increased long-term health benefits,¹ including the reduction of comorbidities, and persistence on a GLP-1 is associate

    11/4/25 12:00:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    $OMDA
    Financials

    Live finance-specific insights

    View All

    Omada Health to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025

    SAN FRANCISCO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2025 results on Thursday, November 6, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same link and will remain accessible for approximately 12 months. Those participating via conference call can pre-register using the following link: https://register-conf.media-ser

    10/16/25 9:01:00 AM ET
    $OMDA
    Medical/Nursing Services
    Health Care

    Omada Health to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

    SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- Omada Health (NASDAQ:OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results on Thursday, August 7, 2025, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details Those participating in the conference call can pre-register using the following link: https://register-conf.media-server.com/register/BIce129368a015484a8f39659a48a1631e. A live audio webcast of the call will also be available online at https://investors.omadahealth.com. A replay will be available shortly after the conclusion of the call at the same l

    7/17/25 4:30:00 PM ET
    $OMDA
    Medical/Nursing Services
    Health Care